Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.

Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.

Disease-modifying antirheumatic drugs are used in virtually all patients with established rheumatoid arthritis. An increasingly large number of new drugs is now available. Furthermore, old therapies are being used in novel ways. Treatment is now begun earlier and patients are rarely left untreated....

Полное описание

Библиографические подробности
Главные авторы:	Emery, P, Luqmani, R, Gordon, C
Формат:	Journal article
Язык:	English
Опубликовано:	1994

Схожие документы

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
по: Abhishek Zanwar, и др.
Опубликовано: (2017-01-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
по: Xia Y, и др.
Опубликовано: (2016-05-01)

The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
по: Edwards, C, и др.
Опубликовано: (2007)

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
по: Gregory Fleury, и др.
Опубликовано: (2017-12-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
по: Yu. V. Muraviev, и др.
Опубликовано: (2018-12-01)

Lung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
по: Yuriy Vladimirovich Murav'ev, и др.
Опубликовано: (2010-12-01)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
по: Smolen, J, и др.
Опубликовано: (2017)

Dynamics of T- and B-lymphocytes in patients with rheumatoid arthritis, receiving biological disease-modifying antirheumatic drugs
по: A. V. Martynova, и др.
Опубликовано: (2022-02-01)

Disease-Modifying Antirheumatic Diets: The New Treatment Modalities for Rheumatoid Arthritis
по: Shweta Khanna, и др.
Опубликовано: (2018-07-01)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
по: Soo-Kyung Cho, и др.
Опубликовано: (2023-07-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
по: A. O. Bobkova, и др.
Опубликовано: (2023-07-01)

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
по: Yinzhu Jin, и др.
Опубликовано: (2023-11-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
по: Yinzhu Jin, и др.
Опубликовано: (2017-07-01)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
по: Emma Sullivan, и др.
Опубликовано: (2020-04-01)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
по: Judge, AD, и др.
Опубликовано: (2017)

Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis
по: Bong-Woo Lee, и др.
Опубликовано: (2024-09-01)

Comparison of the Effect of Disease: Modifying Antirheumatic Drugs Alone or in Combination with Biologic Drugs in the Outcome of Patients with Rheumatoid Arthritis
по: Maryam Mousavi, и др.
Опубликовано: (2019-01-01)

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.
по: Griffiths, R, и др.
Опубликовано: (2001)

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
по: Griffiths, R, и др.
Опубликовано: (2000)

Predictors of radiological progression of rheumatoid arthritis while receiving conventional synthetic disease-modifying antirheumatic drugs
по: O. B. Iaremenko, и др.
Опубликовано: (2024-12-01)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
по: Giovanni Adami, и др.
Опубликовано: (2023-01-01)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
по: van Heuckelum M, и др.
Опубликовано: (2019-07-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
по: Ko-Jen Li, и др.
Опубликовано: (2021-07-01)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
по: Stefan Winkler, и др.
Опубликовано: (2021-11-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
по: Yu. V. Muravyev, и др.
Опубликовано: (2018-09-01)

Initiation of Disease‐Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late‐Onset Rheumatoid Arthritis
по: Jiha Lee, и др.
Опубликовано: (2023-12-01)

Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
по: Gulsen Ozen, и др.
Опубликовано: (2019-09-01)

Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
по: Jon T. Giles, и др.
Опубликовано: (2021-06-01)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
по: Yinan Huang, и др.
Опубликовано: (2023-09-01)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
по: Kemper Alex R, и др.
Опубликовано: (2012-03-01)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
по: Susan Siyu Wang, и др.
Опубликовано: (2023-07-01)

Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain
по: Blanca Hernández Cruz, и др.
Опубликовано: (2020-10-01)

EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
по: A. A. Abramkin, и др.
Опубликовано: (2017-09-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
по: A. E. Karateev, и др.
Опубликовано: (2022-09-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
по: E. N. Koltsova, и др.
Опубликовано: (2022-12-01)

Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy
по: Irma Convertino, и др.
Опубликовано: (2023-09-01)

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database
по: Wan Xiong, и др.
Опубликовано: (2024-11-01)

Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study
по: Carl Turesson, и др.
Опубликовано: (2024-02-01)

In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls
по: Helene Broch Tenstad, и др.
Опубликовано: (2021-10-01)

Use of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Supporting Shared Decision‐Making Between Patients With Cancer and Clinicians
по: Namrata Singh, и др.
Опубликовано: (2023-06-01)